For the quarter ending 2026-03-31, NTLA made $15,048K in revenue. -$97,503K in net income. Net profit margin of -647.95%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 15,048 | 23,017 | 13,782 | 14,245 |
| Research and development | 80,737 | 88,652 | 94,747 | 97,035 |
| General and administrative | 34,843 | 33,075 | 30,512 | 27,206 |
| Total operating expenses | 115,580 | 121,727 | 125,259 | 124,241 |
| Operating loss | -100,532 | -98,710 | -111,477 | -109,996 |
| Interest income | 5,205 | 6,476 | 6,714 | 7,402 |
| Change in fair value of investments, net | -904 | -3,552 | 3,439 | 1,339 |
| Loss from equity method investment | - | 0* | - | - |
| Change in fair value of contingent consideration | - | 0* | - | - |
| Total other income, net | 4,301 | 2,924 | 10,153 | 8,741 |
| Net loss | -96,231 | -95,786 | -101,324 | -101,255 |
| Unrealized (loss) gain on marketable securities | -1,272 | 42 | 337 | -404 |
| Other comprehensive gain from equity method investment | - | 0 | - | - |
| Comprehensive loss | -97,503 | -95,744 | -100,987 | -101,659 |
| Basic EPS | -0.81 | -0.825 | -0.92 | -0.98 |
| Diluted EPS | -0.81 | -0.825 | -0.92 | -0.98 |
| Basic Average Shares | 118,490,000 | 116,084,000 | 110,188,000 | 103,732,000 |
| Diluted Average Shares | 118,490,000 | 116,084,000 | 110,188,000 | 103,732,000 |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)